• Verona Pharma PLC VRNA.OQ reported a quarterly adjusted loss of 40 cents​​ per share for the quarter ended December 31, lower than the same quarter last year, when the company reported EPS of -18 cents. The mean expectation of six analysts for the quarter was for a loss of 29 cents per share. Wall Street expected results to range from -54 cents to -16 cents per share.

• Revenue was $36.66 million​; analysts expected $33.05 million.

• Verona Pharma PLC's reported EPS for the quarter was a loss of 40 cents​.

• The company reported a quarterly loss of $33.83 million.

• Verona Pharma PLC shares had risen by 36.8% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 34% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Verona Pharma PLC is $72.00

This summary was machine generated from LSEG data February 27 at 02:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)